Platelets as immune mediators: their role in host defense responses and sepsis.

PubWeight™: 1.04‹?› | Rank: Top 15%

🔗 View Article (PMC 3042496)

Published in Thromb Res on November 13, 2010

Authors

Zhenyu Li1, Fanmuyi Yang, Steve Dunn, A Kendall Gross, Susan S Smyth

Author Affiliations

1: The Division of Cardiovascular Medicine, The Gill Heart Institute, Lexington, KY 40536-0509, United States.

Associated clinical trials:

Study of Platelet Activation in Septic Shock Patients (PASS) | NCT02635854

The INFUSE Trial - Intervening With Platelet Transfusions in Sepsis (INFUSE) | NCT03090919

Articles citing this

Platelets direct monocyte differentiation into epithelioid-like multinucleated giant foam cells with suppressive capacity upon mycobacterial stimulation. J Infect Dis (2014) 2.69

Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 2.62

Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. Anesthesiology (2016) 1.51

Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscler Thromb Vasc Biol (2014) 1.50

Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol (2011) 1.26

Why are sex and gender important to basic physiology and translational and individualized medicine? Am J Physiol Heart Circ Physiol (2014) 1.15

Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05

Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev (2014) 1.03

Mean platelet volume: a controversial marker of disease activity in Crohn's disease. Eur J Med Res (2012) 0.91

Discrepant fibrinolytic response in plasma and whole blood during experimental endotoxemia in healthy volunteers. PLoS One (2013) 0.88

Leukocyte- and platelet-derived microvesicle interactions following in vitro and in vivo activation of toll-like receptor 4 by lipopolysaccharide. PLoS One (2011) 0.80

Suppressive effect of exogenous carbon monoxide on endotoxin-stimulated platelet over-activation via the glycoprotein-mediated PI3K-Akt-GSK3β pathway. Sci Rep (2016) 0.78

Rupture Forces among Human Blood Platelets at different Degrees of Activation. Sci Rep (2016) 0.78

New strategy for sepsis: Targeting a key role of platelet-neutrophil interaction. Burns Trauma (2014) 0.77

Micro-concentration Lipopolysaccharide as a Novel Stimulator of Megakaryocytopoiesis that Synergizes with IL-6 for Platelet Production. Sci Rep (2015) 0.76

Suppressive effect of CORM-2 on LPS-induced platelet activation by glycoprotein mediated HS1 phosphorylation interference. PLoS One (2013) 0.76

Virulence and thrombocyte affectation of two Aspergillus terreus isolates differing in amphotericin B susceptibility. Med Microbiol Immunol (2013) 0.76

Improvement of prognostic performance in severely injured patients by integrated clinico-transcriptomics: a translational approach. Crit Care (2015) 0.75

Thoracic epidural anesthesia decreases endotoxin-induced endothelial injury. BMC Anesthesiol (2014) 0.75

The potential of antimicrobials to induce thrombocytopenia in critically ill patients: data from a randomized controlled trial. PLoS One (2013) 0.75

IgM-Enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis: A Before-After Cohort Study. PLoS One (2016) 0.75

Articles cited by this

Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med (2007) 8.58

Platelet activation and atherothrombosis. N Engl J Med (2007) 6.18

Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature (1992) 2.48

Platelets express functional Toll-like receptor-4. Blood (2005) 2.37

The interaction of bacterial pathogens with platelets. Nat Rev Microbiol (2006) 2.26

Platelets, petechiae, and preservation of the vascular wall. N Engl J Med (2008) 2.25

Platelet functions beyond hemostasis. J Thromb Haemost (2009) 2.23

Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med (2010) 2.08

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood (2005) 2.03

Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science (2009) 1.74

Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol (2009) 1.70

Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol (2008) 1.57

Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost (2006) 1.55

The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol (2009) 1.51

Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost (2007) 1.47

Thrombocytopenia in a surgical ICU. Chest (1999) 1.45

Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by Staphylococcus aureus clumping factor A. Mol Microbiol (2005) 1.37

Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood (2002) 1.36

Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood (2006) 1.33

Platelet count decline: an early prognostic marker in critically ill patients with prolonged ICU stays. Chest (2007) 1.33

Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest (2010) 1.30

The platelet proteome. Curr Opin Hematol (2009) 1.29

Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets (2009) 1.26

Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost (2005) 1.23

In vivo effects of lipopolysaccharide and TLR4 on platelet production and activity: implications for thrombotic risk. J Appl Physiol (1985) (2006) 1.13

Toll-like receptor 4 ligand can differentially modulate the release of cytokines by human platelets. Br J Haematol (2008) 1.12

Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost (2005) 1.11

Thrombocytopenia in the intensive care unit. Chest (1993) 1.11

The role of platelets in acute lung injury (ALI). Front Biosci (Landmark Ed) (2009) 1.10

Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med (2007) 1.09

LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood (2002) 1.04

Beneficial effect of glycoprotein IIb/IIIa inhibitor (AZ-1) on endothelium in Escherichia coli endotoxin-induced shock. Crit Care Med (2001) 0.90

Giulio Bizzozero: a pioneer of cell biology. Nat Rev Mol Cell Biol (2001) 0.89

7E3 F(ab')2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli. Blood (1997) 0.89

Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost (2009) 0.89

Human platelets can activate peripheral blood B cells and increase production of immunoglobulins. Exp Hematol (2007) 0.87

Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery. Arch Intern Med (2009) 0.87

Early endotoxin-mediated haemostatic and inflammatory responses in the clopidogrel-treated pig. Platelets (2005) 0.86

Lipopolysaccharide induces sCD40L release through human platelets TLR4, but not TLR2 and TLR9. Intensive Care Med (2006) 0.86

Articles by these authors

Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest (2005) 2.46

Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood (2011) 2.27

Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80

Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem (2009) 1.78

Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52

Periostin mediates vascular smooth muscle cell migration through the integrins alphavbeta3 and alphavbeta5 and focal adhesion kinase (FAK) pathway. Atherosclerosis (2009) 1.33

Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets (2008) 1.27

Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol (2009) 1.23

Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21

Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20

Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng Des Sel (2007) 1.19

Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res (2007) 1.19

Src family kinases mediate neutrophil adhesion to adherent platelets. Blood (2006) 1.16

Autotaxin production of lysophosphatidic acid mediates allergic asthmatic inflammation. Am J Respir Crit Care Med (2013) 1.15

Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem (2011) 1.11

Integrin αIIbβ3: from discovery to efficacious therapeutic target. Circ Res (2013) 1.11

Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions. Clin Sci (Lond) (2011) 1.10

Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice. J Lipid Res (2013) 1.09

Mice with targeted inactivation of ppap2b in endothelial and hematopoietic cells display enhanced vascular inflammation and permeability. Arterioscler Thromb Vasc Biol (2014) 1.08

A phosphatidic acid binding/nuclear localization motif determines lipin1 function in lipid metabolism and adipogenesis. Mol Biol Cell (2010) 1.07

Src-family kinases mediate an outside-in signal necessary for beta2 integrins to achieve full activation and sustain firm adhesion of polymorphonuclear leucocytes tethered on E-selectin. Biochem J (2006) 1.05

Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nat Commun (2013) 1.05

Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler Thromb Vasc Biol (2012) 1.04

CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol (2006) 1.04

Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res (2013) 1.03

Apoptosis of the thick ascending limb results in acute kidney injury. J Am Soc Nephrol (2008) 1.03

Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol (2009) 1.03

Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway. Arterioscler Thromb Vasc Biol (2008) 1.02

Distinct roles for Rap1b protein in platelet secretion and integrin αIIbβ3 outside-in signaling. J Biol Chem (2011) 1.01

Reduced EGFR causes abnormal valvular differentiation leading to calcific aortic stenosis and left ventricular hypertrophy in C57BL/6J but not 129S1/SvImJ mice. Am J Physiol Heart Circ Physiol (2009) 0.99

Arguing the case for the autotaxin-lysophosphatidic acid-lipid phosphate phosphatase 3-signaling nexus in the development and complications of atherosclerosis. Arterioscler Thromb Vasc Biol (2014) 0.94

Evidence of mobilization of pluripotent stem cells into peripheral blood of patients with myocardial ischemia. Exp Hematol (2010) 0.92

A self-powered ZnO-nanorod/CuSCN UV photodetector exhibiting rapid response. Adv Mater (2012) 0.91

Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways. Biochem J (2011) 0.91

Enhanced proliferation and migration of vascular smooth muscle cells in response to vascular injury under hyperglycemic conditions is controlled by beta3 integrin signaling. Int J Biochem Cell Biol (2010) 0.91

Measurement of autotaxin/lysophospholipase D activity. Methods Enzymol (2007) 0.90

Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells. J Biol Chem (2010) 0.90

Platelet secretion and hemostasis require syntaxin-binding protein STXBP5. J Clin Invest (2014) 0.89

Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev (2013) 0.87

Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol (2011) 0.87

LiNbO3--a new material for artificial photosynthesis. IEEE Trans Ultrason Ferroelectr Freq Control (2011) 0.87

Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86

CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury. PLoS One (2011) 0.85

Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis (2013) 0.84

Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc Med (2009) 0.84

Acoustic enhancement of polymer/ZnO nanorod photovoltaic device performance. Adv Mater (2013) 0.84

Parent-of-origin effects on cardiac response to pressure overload in mice. Am J Physiol Heart Circ Physiol (2009) 0.84

Effects of unfractionated heparin and glycoprotein IIb/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils. Arterioscler Thromb Vasc Biol (2007) 0.84

Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One (2012) 0.83

Integrin-mediated cell surface recruitment of autotaxin promotes persistent directional cell migration. FASEB J (2013) 0.83

Synergistic effect of anemia and red blood cells transfusion on inflammation and lung injury. Adv Hematol (2012) 0.83

Biomass-derived carbon quantum dot sensitizers for solid-state nanostructured solar cells. Angew Chem Int Ed Engl (2015) 0.83

Light-emitting diodes with semiconductor nanocrystals. Angew Chem Int Ed Engl (2008) 0.82

Lysophosphatidic acid and cardiovascular disease: seeing is believing. J Lipid Res (2013) 0.82

Lysophospholipids in coronary artery and chronic ischemic heart disease. Curr Opin Lipidol (2015) 0.81

Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol (2012) 0.81

Recent progress in ZnO-based nanostructured ceramics in solar cell applications. J Nanosci Nanotechnol (2012) 0.81

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost (2014) 0.80

Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B. Cardiol Rev (2015) 0.79

In situ antimony doping of solution-grown ZnO nanorods. Chem Commun (Camb) (2009) 0.79

Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study. J Thromb Thrombolysis (2012) 0.79

Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis (2011) 0.79

Inflammation and thrombosis in cardiovascular disease. Curr Opin Hematol (2013) 0.79

Value of pharmacy residency training: a survey of the academic medical center perspective. Am J Health Syst Pharm (2012) 0.79

Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses. Circ Cardiovasc Interv (2012) 0.78

Enhanced platelet reactivity and thrombosis in Apoe-/- mice exposed to cigarette smoke is attenuated by P2Y12 antagonism. Thromb Res (2010) 0.78

Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development. Arterioscler Thromb Vasc Biol (2010) 0.78

Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis (2014) 0.78

The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism. PLoS One (2012) 0.78

Pathophysiology and pharmacologic treatment of venous thromboembolism. Curr Drug Targets (2014) 0.77

The effect of rosuvastatin on platelet-leukocyte interactions in the setting of acute coronary syndrome. J Am Coll Cardiol (2015) 0.77

Preventing platelet thrombosis with a PAR1 pepducin. Circulation (2012) 0.77

The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome. J Thromb Thrombolysis (2015) 0.77

Novel mediators and biomarkers of thrombosis. J Thromb Thrombolysis (2014) 0.77

Tissue necrosis factor α and targeting its receptor in ischaemic heart disease. Heart (2013) 0.76

In-stent restenosis: more fuel for the fire. Am Heart J (2002) 0.76

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J (2010) 0.75

Fibrinolytic therapy versus primary percutaneous coronary interventions for ST-segment elevation myocardial infarction in Kentucky: time to establish systems of care? South Med J (2013) 0.75

Connexin 37 counteracts clotting. Circulation (2011) 0.75

Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions. Curr Cardiol Rev (2016) 0.75

Platelet function analysis: at the edge of meaning. Thromb Haemost (2009) 0.75

Invasive coronary vasoreactivity testing to diagnose microvascular dysfunction in women. JACC Cardiovasc Interv (2012) 0.75

Targeting platelet thrombin receptor signaling to prevent thrombosis. Pharmaceuticals (Basel) (2013) 0.75

Enhanced performance with bismuth ferrite perovskite in ZnO nanorod solid state solar cells. Nanoscale (2014) 0.75

Anti-platelet therapy. Curr Drug Targets (2011) 0.75

Room temperature synthesis of crystalline alpha-Fe2O3 nanoparticles. J Nanosci Nanotechnol (2011) 0.75

Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother (2007) 0.75

Enhanced Photocatalytic Activity of Heterostructured Ferroelectric BaTiO3/α-Fe2O3 and the Significance of Interface Morphology Control. ACS Appl Mater Interfaces (2017) 0.75

Chemical protection of ZnO nanorods at ultralow pH To form a hierarchical BiFeO3/ZnO core-shell structure. ACS Appl Mater Interfaces (2015) 0.75

The case against routine aspirin use for primary prevention in low-risk adults. Am Fam Physician (2011) 0.75

Preventing Harm in the ICU-Building a Culture of Safety and Engaging Patients and Families. Crit Care Med (2017) 0.75

Platelet-mediated thrombosis and drug-eluting stents. Circ Cardiovasc Interv (2011) 0.75

Influence of annealing on composition and optical properties of CdTe nanoparticle layer-by-layer films. J Nanosci Nanotechnol (2011) 0.75

Recruitment and retention of rural general practitioners: a marketing approach reveals new possibilities. Aust J Rural Health (2007) 0.75